Healthcare / BiotechnologyNasdaqGM
$7.77
-0.15 (-1.89%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-60.4M · quality 51.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
16/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$221M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-30.7%
↓Gross Margin
N/A
•Debt/Equity
0.12
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2018–2025 · 7 años de histórico normalizado
Revenue CAGR
+23.0%
FCF CAGR
—
FCF margin
-110.8%
FCF / Net income
1.13x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $67.2M · net income $-65.8M · FCF $-74.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | $67.2M | $67.2M | $138.4M | $157.7M | $205.8M | $12.4M | $9.5M | $20.8M | $15.8M |
| Net Income | $-65.8M | $-65.8M | $-80.9M | $-29.7M | $9.3M | $-203.7M | $-72.1M | $-26.0M | $-21.8M |
| EBITDA | $-62.7M | $-62.7M | $-77.4M | $-24.2M | $13.7M | $-201.7M | $-70.6M | $-24.8M | $-21.2M |
| EPS | -2.40 | -2.40 | -3.00 | -1.00 | 0.35 | -7.74 | — | — | — |
| Operating Margin | -113.4% | -113.4% | -69.1% | -49.6% | 5.9% | -1641.3% | -749.8% | -122.7% | -138.5% |
| Net Margin | -97.9% | -97.9% | -58.5% | -18.8% | 4.5% | -1648.0% | -756.3% | -125.0% | -138.3% |
| Balance Sheet | |||||||||
| Debt/Equity | 0.12 | 0.12 | 0.12 | 0.11 | 0.35 | 0.18 | 0.03 | 0.58 | 0.73 |
| Current Ratio | 6.31 | 6.31 | — | — | — | — | — | — | — |
| Cash Flow | |||||||||
| Free Cash Flow | $-74.5M | $-74.5M | $-60.4M | $-21.0M | $24.3M | $-138.4M | $-44.6M | $-7.3M | $-22.2M |
| Returns | |||||||||
| ROE | -30.7% | -30.7% | -33.6% | -10.7% | 3.5% | -89.2% | -18.2% | -100.8% | -159.7% |
| Valuation | |||||||||
| P/E | — | — | — | — | 46.89 | — | — | — | — |
| EV/EBITDA | — | — | — | — | 10.76 | — | — | — | — |
| P/B | 0.99 | 0.99 | 2.01 | 2.99 | 1.64 | — | — | — | — |
| Growth & Yield | |||||||||
| Revenue Growth | -51.4% | -51.4% | -12.3% | -23.3% | — | 29.6% | -54.1% | 32.0% | — |
| EPS Growth | 20.0% | 20.0% | -200.0% | -385.7% | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-38.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-3.00 → -2.40
Residual
-38.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.